Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

Jorge Cortes, Apostolia M. Tsimberidou, Ricardo Alvarez, Deborah Thomas, Miloslav Beran, Hagop Kantarjian, Elihu Estey, Francis J. Giles

Research output: Contribution to journalArticle

Abstract

Purpose: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML. Methods: MTA consisted of Mylotarg 9 mg/m2 intravenously (i.v.) over 2 h on day 1, ara-C 1 g/m2 over 2 h i.v. on days 1 through 5, and topotecan 1.25 mg/m2 by continuous infusion i.v. on days 1 through 5. Results: A group of 17 patients (9 primary resistant, 8 relapsed) with AML or advanced myelodysplastic syndrome (MDS) received 20 courses of MTA. The median age of the patients was 55 years (20-70 years). Two patients (12%) achieved complete remission. The median overall survival was 8.2 weeks. Five patients (29%) developed grade 3/4 hepatic transaminitis, including one patient (6%) who died with hepatic venoocclusive disease. Conclusions: MTA was moderately effective and associated with significant toxicity in patients with refractory AML.

Original languageEnglish (US)
Pages (from-to)497-500
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume50
Issue number6
DOIs
StatePublished - Dec 19 2002
Externally publishedYes

Fingerprint

Pemetrexed
Topotecan
Cytarabine
Acute Myeloid Leukemia
Refractory materials
Toxicity
Anti-Bacterial Agents
Antibodies, Monoclonal, Humanized
gemtuzumab
Antibodies
Liver
Myelodysplastic Syndromes
Anti-Idiotypic Antibodies

Keywords

  • Acute myeloid leukemia
  • Cytarabine
  • Mylotarg
  • Refractory
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. / Cortes, Jorge; Tsimberidou, Apostolia M.; Alvarez, Ricardo; Thomas, Deborah; Beran, Miloslav; Kantarjian, Hagop; Estey, Elihu; Giles, Francis J.

In: Cancer Chemotherapy and Pharmacology, Vol. 50, No. 6, 19.12.2002, p. 497-500.

Research output: Contribution to journalArticle

Cortes, J, Tsimberidou, AM, Alvarez, R, Thomas, D, Beran, M, Kantarjian, H, Estey, E & Giles, FJ 2002, 'Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia', Cancer Chemotherapy and Pharmacology, vol. 50, no. 6, pp. 497-500. https://doi.org/10.1007/s00280-002-0539-y
Cortes, Jorge ; Tsimberidou, Apostolia M. ; Alvarez, Ricardo ; Thomas, Deborah ; Beran, Miloslav ; Kantarjian, Hagop ; Estey, Elihu ; Giles, Francis J. / Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. In: Cancer Chemotherapy and Pharmacology. 2002 ; Vol. 50, No. 6. pp. 497-500.
@article{5a23662a3d814aadb1eb6d3f6bbc51d3,
title = "Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia",
abstract = "Purpose: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML. Methods: MTA consisted of Mylotarg 9 mg/m2 intravenously (i.v.) over 2 h on day 1, ara-C 1 g/m2 over 2 h i.v. on days 1 through 5, and topotecan 1.25 mg/m2 by continuous infusion i.v. on days 1 through 5. Results: A group of 17 patients (9 primary resistant, 8 relapsed) with AML or advanced myelodysplastic syndrome (MDS) received 20 courses of MTA. The median age of the patients was 55 years (20-70 years). Two patients (12{\%}) achieved complete remission. The median overall survival was 8.2 weeks. Five patients (29{\%}) developed grade 3/4 hepatic transaminitis, including one patient (6{\%}) who died with hepatic venoocclusive disease. Conclusions: MTA was moderately effective and associated with significant toxicity in patients with refractory AML.",
keywords = "Acute myeloid leukemia, Cytarabine, Mylotarg, Refractory, Topotecan",
author = "Jorge Cortes and Tsimberidou, {Apostolia M.} and Ricardo Alvarez and Deborah Thomas and Miloslav Beran and Hagop Kantarjian and Elihu Estey and Giles, {Francis J.}",
year = "2002",
month = "12",
day = "19",
doi = "10.1007/s00280-002-0539-y",
language = "English (US)",
volume = "50",
pages = "497--500",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

AU - Cortes, Jorge

AU - Tsimberidou, Apostolia M.

AU - Alvarez, Ricardo

AU - Thomas, Deborah

AU - Beran, Miloslav

AU - Kantarjian, Hagop

AU - Estey, Elihu

AU - Giles, Francis J.

PY - 2002/12/19

Y1 - 2002/12/19

N2 - Purpose: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML. Methods: MTA consisted of Mylotarg 9 mg/m2 intravenously (i.v.) over 2 h on day 1, ara-C 1 g/m2 over 2 h i.v. on days 1 through 5, and topotecan 1.25 mg/m2 by continuous infusion i.v. on days 1 through 5. Results: A group of 17 patients (9 primary resistant, 8 relapsed) with AML or advanced myelodysplastic syndrome (MDS) received 20 courses of MTA. The median age of the patients was 55 years (20-70 years). Two patients (12%) achieved complete remission. The median overall survival was 8.2 weeks. Five patients (29%) developed grade 3/4 hepatic transaminitis, including one patient (6%) who died with hepatic venoocclusive disease. Conclusions: MTA was moderately effective and associated with significant toxicity in patients with refractory AML.

AB - Purpose: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML. Methods: MTA consisted of Mylotarg 9 mg/m2 intravenously (i.v.) over 2 h on day 1, ara-C 1 g/m2 over 2 h i.v. on days 1 through 5, and topotecan 1.25 mg/m2 by continuous infusion i.v. on days 1 through 5. Results: A group of 17 patients (9 primary resistant, 8 relapsed) with AML or advanced myelodysplastic syndrome (MDS) received 20 courses of MTA. The median age of the patients was 55 years (20-70 years). Two patients (12%) achieved complete remission. The median overall survival was 8.2 weeks. Five patients (29%) developed grade 3/4 hepatic transaminitis, including one patient (6%) who died with hepatic venoocclusive disease. Conclusions: MTA was moderately effective and associated with significant toxicity in patients with refractory AML.

KW - Acute myeloid leukemia

KW - Cytarabine

KW - Mylotarg

KW - Refractory

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0036453018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036453018&partnerID=8YFLogxK

U2 - 10.1007/s00280-002-0539-y

DO - 10.1007/s00280-002-0539-y

M3 - Article

C2 - 12451477

AN - SCOPUS:0036453018

VL - 50

SP - 497

EP - 500

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -